Related Experiment Video

Updated: Jun 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Bleeding complications of anticoagulant therapy]

J Gumulec1, P Kessler, V Procházka

  • 1Hemato-onkologické a transfuzní centrum FN Ostrava. jaromir.gumulec@fnspo.cz

Vnitrni Lekarstvi
|April 22, 2009
PubMed

Insights

Anticoagulant therapy is crucial for preventing blood clots but carries bleeding risks. This review covers managing bleeding and overdosing with new anticoagulants lacking specific reversal agents.

Area of Science:

  • Internal Medicine
  • Pharmacology
  • Hematology

Context:

  • Anticoagulant therapy is a common medical intervention for preventing and treating thrombotic events.
  • Omission of adequate anticoagulant prophylaxis is a recognized medical error, particularly for moderate- to high-risk patients.
  • Bleeding is a significant complication associated with all anticoagulants.

Purpose:

  • To evaluate the bleeding risk associated with current anticoagulants.
  • To review existing and experimental agents for reversing anticoagulation.
  • To provide recommendations for managing major bleeding and asymptomatic overdosing of anticoagulants.

Summary:

  • Unlike older anticoagulants like heparin and warfarin, many newer agents (direct/indirect inhibitors of factors Xa/IIa) lack specific reversal agents.
  • The clinical use of novel anticoagulants is challenging due to the absence of readily available laboratory tests for monitoring.
  • This review examines bleeding risks, reversal strategies, and management guidelines for anticoagulant-related bleeding and overdosing.

Impact:

  • Provides critical guidance for clinicians managing patients on anticoagulant therapy, especially those using novel agents.
  • Addresses the unmet need for effective reversal strategies and monitoring tools for newer anticoagulants.
  • Aims to improve patient safety and optimize the benefit-risk profile of anticoagulant treatments.

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...